Norepinephrine Plus Dobutamine Versus Epinephrine Alone for the Management of Septic Shock (CATS)

This study has been completed.
Sponsor:
Collaborator:
Assistance Publique - Hôpitaux de Paris
Information provided by:
University of Versailles
ClinicalTrials.gov Identifier:
NCT00148278
First received: September 1, 2005
Last updated: July 21, 2010
Last verified: July 2010

September 1, 2005
July 21, 2010
October 1999
December 2004   (final data collection date for primary outcome measure)
28 Day mortality [ Time Frame: 28 Day ] [ Designated as safety issue: Yes ]
28-day mortality
Complete list of historical versions of study NCT00148278 on ClinicalTrials.gov Archive Site
  • -28-day survival distribution [ Time Frame: Day 28 ] [ Designated as safety issue: Yes ]
  • -Survival rate at days 14, 28, 90, 6 months and 1 year. [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • -Rate of patients with secondary care limitation [ Time Frame: one year ] [ Designated as safety issue: No ]
  • -Organ failure between randomization and day 28. [ Time Frame: Day 28 ] [ Designated as safety issue: Yes ]
  • -Serious adverse events between randomization and exit of intensive care unit. [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • -Onset of a reversible clinical event between randomization and exit of intensive care unit (bronchospasm, cutaneous rash, tachycardia) [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • -Time on vasopressors [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
  • -Time in intensive care unit [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • -Time in hospital [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • -Costs [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
  • -28-day survival distribution
  • -Survival rate at days 14, 28, 90, 6 months and 1 year.
  • -Rate of patients with secondary care limitation
  • -Rate of hemodynamic success
  • -Organ failure between randomization and day 28.
  • -Serious adverse events between randomization and exit of intensive care unit.
  • -Onset of a reversible clinical event between randomization and exit of intensive care unit (bronchospasm, cutaneous rash, tachycardia)
  • -Time on vasopressors
  • -Time in intensive care unit
  • -Time in hospital
  • -Costs
Not Provided
Not Provided
 
Norepinephrine Plus Dobutamine Versus Epinephrine Alone for the Management of Septic Shock
Prospective, Multicenter, Randomized, Double-Blind Study Comparing Safety and Efficacy of Norepinephrine Plus Dobutamine Versus Epinephrine Alone in Septic Shock.

Catecholamines infusion is a major component of septic shock management. International guidelines recommend that norepinephrine should be preferred to epinephrine, though phase III trials are lacking. The present study aimed at comparing the efficacy and safety of norepinephrine plus dobutamine to that of epinephrine in adults with septic shock.

The french Conference on Consensus on catecholamines use in septic shock has underlined the importance of carrying out a clinical trial to clarify the use of epinephrine, norepinephrine and dobutamine in the management of multiple organ failure associated with severe sepsis. The main objective of the study was therefore to compare the effects of the combination of dobutamine and norepinephrine to those of epinephrine alone in patients with septic shock. In this purpose, patients were randomly assigned to receive either epinephrine or norepinephrine plus dobutamine and drugs were titrated to maintain blood pressure over 70 mmHg. Main outcome was 28-day mortality.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Septic Shock
  • Severe Sepsis
  • Infections
  • Drug: norepinephrine and dobutamine
    continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
  • Drug: epinephrine plus placebo of dobutamine
    epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
  • Experimental: 1
    norepinephrine plus dobutamine
    Intervention: Drug: norepinephrine and dobutamine
  • Active Comparator: 2
    epinephrine
    Intervention: Drug: epinephrine plus placebo of dobutamine
Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, Troche G, Ricard JD, Nitenberg G, Papazian L, Azoulay E, Bellissant E; CATS Study Group. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007 Aug 25;370(9588):676-84.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
330
December 2005
December 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults over 18 years
  • Informed consent

Presenting from less than 7 days :

  • One or more infectious site
  • At least 2 of the following criteria: temperature > 38°C or < 36.5°C, respiratory rate > 20 breaths per min or PaCO2 < 32 mmHg or mechanical ventilation, heart rate > 90 beats/min, white blood cell count > 12,000/mm3 or < 4,000/mm3
  • At least 2 of the following criteria: PaO2/FiO2 ratio <280 mmHg (if mechanical ventilation, urinary output of less than 0.5 mL/kg of body weight or < 30 mL/h at least 1 hour, plasma lactate > 2 mmol/L, platelet count < 100,000 /mm3

And presenting from at least 24 hours:

  • Systolic blood pressure < 90 mmHg or mean blood pressure < 70 mmHg (for at least 30 min);
  • 1000 mL fluid replacement or pulmonary capillary wedge pressure > 12 mmHg
  • Dopamine infusion at 15 µg/kg/min for at least 1 hour, or epinephrine or norepinephrine in first intention

Exclusion Criteria:

  • Pregnant woman
  • Obstructive cardiomyopathy
  • Acute coronary disease
  • Non infectious shock
  • Care limitation
  • White blood cell count < 500 /mm3
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00148278
AFSSAPS 990931, AOM97123, CIC0203/001
Yes
Djillali Annane, Assistance Publique Hôpitaux de Paris
University of Versailles
Assistance Publique - Hôpitaux de Paris
Study Director: Djillali Annane, MD, PhD Assistance Publique Hôpitaux de Paris - University of Versailles
Study Chair: Eric Bellissant, MD, PhD CHU Rennes
University of Versailles
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP